2026-525260-18-00RecruitingPhase 2
Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).
Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Jul 2026
Brief summary (registry, in English)
To demonstrate non-futility of indapamide treatment for the prevention of disability worsening in PPMS and SPMS
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 25 Sept 2026
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Multiple sclerosis
- EU CT number
- 2026-525260-18-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 84
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary or secondary progressive multiple sclerosis who have moderate walking disability, to test oral indapamide.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Primary progressive (PPMS) or secondary progressive (SPMS) multiple sclerosis. Expanded Disability Status Scale score between 4.0 and 6.5. Timed 25 foot walk of 5 seconds or more (PPMS) or 9 seconds or more (SPMS).
- Earlier treatment
- Cannot be using siponimod, ocrelizumab, natalizumab or other treatment for relapsing-remitting MS. Cannot be using corticosteroids, Fampridine or 4-aminopyridine.
Main reasons for not taking part
- Kidney problems with eGFR below 30ml/min per 1.73 m2
- Recent gadolinium enhancement or new T2 lesions on MRI in the 6 months before joining
- Heart rhythm problems or a long QT interval
- Serious liver problems
- Pregnant or breast-feeding, or allergic to indapamide
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who receive treatment with Botulinum toxin in the leg muscles during the trial
- Individuals with recent gadolinium enhancement or new T2 lesions on brain/spinal cord MRI in the 6 months prior to inclusion
- Concomitant use of corticosteroids
Other illness
- Individuals who use siponimod, ocrelizumab, natalizumab or other disease-modifying treatment for RRMS
- Individuals with significant hepatic impairment (pre-existing or developing during the trial)
- Individuals with cardiac arrhythmia
- Individuals with an allergy or other intolerability to indapamide
Lab values
- Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2
- Individuals with a prolonged QT interval: individuals with frequency corrected QT (QTc) intervals of more than 450ms (men) or 470ms (women) at the screening examination will not be included in the study, and participants with QTc intervals of greater than 500ms on any of the other ECG examinations throughout the study will be excluded from the study.
Other
- Individuals who start Baclofen or Tizanidine during the trial
- Individuals who increase the dose of Baclofen or Tizanidine during the trial
- Individuals with clinically significant abnormal screening labs
- Individuals who are pregnant or currently breast-feeding
- Individuals who use Fampridine or 4-aminopyridine
- Individuals who start Fampridine or 4-aminopyridine during the trial
Who the study is looking for
- Written informed consent obtained
- Aged between 18 and 65 years
- Diagnosed with PPMS or SPMS, according to current diagnostic criteria
- Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive
- Screening timed 25 foot walk (average of two trials) of 5 seconds or more for people with PPMS, or of 9 seconds or more for people with SPMS
- Use of effective methods of contraception for women of childbearing potential
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.